ea0011oc20 | Clinical endocrinology | ECE2006
Webb SM
, Colao A
, Caron P
, Carvalheiro M
, Ertürk E
, Pokrajac-Simeunovic A
, Schopohl J
, Tsagarakis S
, Pearson IV
, Badia X
, Caglio S
, Vincenzi B
The primary aim of this study, the largest European, single evaluation, observational trial to date, was to evaluate the impact of acromegaly on health-related quality of life (HRQoL) in patients with biochemically documented active disease, receiving Sandostatin® LAR® at a dose prescribed by their physician for at least 3 months. Secondary objectives were to investigate the relationships between HRQoL and subpopulations based on exploratory var...